Lecca L 1

1. Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis
2. Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial
3. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial
4. Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis
5. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
6. All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings
7. Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial
8. Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications
1